Investigational drugs for treating psoriatic arthritis

Bibliography

• Gladman DD. Early psoriatic arthritis. Rheum Dis Clin North Am 2012;38(2):373-86
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007;146(6):406-15
   PubMed Web of Science ®Google Scholar
• Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 2012;51(8):1368-77
   PubMed Web of Science ®Google Scholar
• Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of veterans affairs cooperative study. Arthritis Rheum 1996;39(12):2013-20
   PubMed Web of Science ®Google Scholar
• Black RL, O’Brien WM, Vanscott EJ, et al. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA 1964;189:743-7
   PubMed Web of Science ®Google Scholar
• Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;4):376-81
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Gaujoux-Viala C, et al. European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheumatic Dis 2012;71(1):4-12
   PubMed Web of Science ®Google Scholar
• Goldminz AM, Gottlieb AB. Ustekinumab for psoriasis and psoriatic arthritis. J Rheumatol Suppl 2012;89:86-9
   PubMedGoogle Scholar
• Tsoi LC, Spain SL, Knight J, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet 2012;44(12):1341-8
   PubMed Web of Science ®Google Scholar
• Prieto-Perez R, Cabaleiro T, Dauden E, et al. Genetics of psoriasis and pharmacogenetics of biological drugs. Autoimmune Dis 2013;2013:613086
   PubMedGoogle Scholar
• Hebert HL, Ali FR, Bowes J, et al. Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. Br J Dermatol 2012;166(3):474-82
   PubMed Web of Science ®Google Scholar
• O’Rielly DD, Rahman P. Genetics of susceptibility and treatment response in psoriatic arthritis. Nat Rev Rheumatol 2011;7(12):718-32
   PubMed Web of Science ®Google Scholar
• Elder JT. Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun 2009;10(3):201-9
   PubMed Web of Science ®Google Scholar
• Weitz JE, Ritchlin CT. Mechanistic insights from animal models of psoriasis and psoriatic arthritis. Curr Rheumatol Rep 2013;15(11):377
   PubMed Web of Science ®Google Scholar
• Sherlock JP, Joyce-Shaikh B, Turner SP, et al. Il-23 induces spondyloarthropathy by acting on ror-gammat+ cd3+cd4-cd8- entheseal resident t cells. Nat Med 2012;18(7):1069-76
   PubMed Web of Science ®Google Scholar
• Huh JR, Englund EE, Wang H, et al. Identification of potent and selective diphenylpropanamide rorgamma inhibitors. ACS Med Chem Lett 2013;4(1):79-84
   PubMed Web of Science ®Google Scholar
• Wang C, Wu L, Bulek K, et al. The psoriasis-associated d10n variant of the adaptor act1 with impaired regulation by the molecular chaperone hsp90. Nat Immunol 2013;14(1):72-81
   PubMed Web of Science ®Google Scholar
• Belge K, Bruck J, Ghoreschi K. Advances in treating psoriasis. F1000Prime Rep 2014;6:4
   PubMedGoogle Scholar
• Palfreeman AC, McNamee KE, McCann FE. New developments in the management of psoriasis and psoriatic arthritis: A focus on apremilast. Drug Des Devel And Ther 2013;7:201-10
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a camp phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010;159(4):842-55
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014; doi:10.1136/annrheumdis-2013-205056
   Google Scholar
• Cutulo M, Myerson GE, Fleischmann RM, et al. Long-term (52-week; results of a phase 3 randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2). Arthritis Rheum 2013;65(Suppl 10):S346-7
   Google Scholar
• Gladman DD, Mease PJ, Kavanaugh A, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvements in enthesitis and dactylitis in patients with psoriatic arthritis: pooled results from three phase 3, randomized, controlled trials. Arthritis Rheum 2013;65(Suppl 10):S347
   Google Scholar
• Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012;64(10):3156-67
   PubMed Web of Science ®Google Scholar
• Strand V, Schett G, Hu C, Stevens RM. Patient-reported health-related quality of life with apremilast for psoriatic arthritis: a phase ii, randomized, controlled study. J Rheumatol 2013;40(7):1158-65
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228(1):273-87
   PubMed Web of Science ®Google Scholar
• Norman P. Selective jak1 inhibitor and selective tyk2 inhibitor patents. Expert Opin Ther Pat 2012;22(10):1233-49
   PubMed Web of Science ®Google Scholar
• Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203214s002lbl.pdf
   Google Scholar
• Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367(6):495-507
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012;167(3):668-77
   PubMed Web of Science ®Google Scholar
• Russolillo A, Iervolino S, Peluso R, et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology 2013;52(1):62-7
   PubMed Web of Science ®Google Scholar
• Keystone E, Taylor P, Genovese M, et al. 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional DMARDs in patients with rheumatoid arthritis. Ann Rheum Dis 2012;71(Suppl 3):152
   Google Scholar
• Vanhoutte FP, Mazour M, Namour N, et al. Efficacy and safety of GLPG0634, a selective JAK1 inhibitor, after short-term treatment of rheumatoid arthritis; results of a phase IIA trial. Ann Rheum Dis 2012;71(Suppl 3):145
   Google Scholar
• Stump KL, Lu LD, Dobrzanski P, et al. A highly selective, orally active inhibitor of janus kinase 2, cep-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Res Ther 2011;13(2):R68
   PubMed Web of Science ®Google Scholar
• Genovese MC, van Vollenhoven R, Bloom BJ, et al. A phase 2b, 12-week study of VX-509, an oral selective janus kinase 3 inhibitor, in combination with background methotrexate in rheumatoid arthritis. Presented as a late breaking abstract at the American College of Rheumatology Annual Scientific Meeting; 2013. Available from: http://www.acrannualmeeting.org/Content/images/pdf/2013%20ACR%20Late-Breaking%20Accepted%20Abstracts.pdf
   Google Scholar
• Nijjar JS, Tindell A, McInnes IB, Siebert S. Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis. Rheumatology 2013;52(9):1556-62
   PubMed Web of Science ®Google Scholar
• Coffey G, DeGuzman F, Inagaki M, et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther 2012;340(2):350-9
   PubMed Web of Science ®Google Scholar
• Altmeyer PJ, Matthes U, Pawlak F, et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994;3:977-81
   Google Scholar
• Reich K, Thaci D, Mrowietz U, et al. Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis—a retrospective study (FUTURE). J Dtsch Dermatol Ges 2009;7:603-11
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Brück J, Kellerer C, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 2011;208:2291-303
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
   PubMed Web of Science ®Google Scholar
• Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of th1 and th17 t cells. J Invest Dermatol 2008;128(5):1207-11
   PubMed Web of Science ®Google Scholar
• Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 2012;64(1):99-109
   PubMed Web of Science ®Google Scholar
• Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper t cells. Nat Immunol 2007;8(9):950-7
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled psummit 1 trial. Lancet 2013;382(9894):780-9
   PubMed Web of Science ®Google Scholar
• Weaver CT, Hatton RD, Mangan PR, Harrington LE. Il-17 family cytokines and the expanding diversity of effector t cell lineages. Ann Rev Immunol 2007;25:821-52
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase ii dose-ranging study. Br J Dermatol 2013;168(2):412-21
   PubMed Web of Science ®Google Scholar
• McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17a monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase ii proof-of-concept trial. Ann Rheum Dis 2014;73(2):349-56
   PubMed Web of Science ®Google Scholar
• Genovese MC, Van den Bosch F, Roberson SA, et al. Ly2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase i randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010;62(4):929-39
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366(13):1190-9
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366(13):1181-9
   PubMed Web of Science ®Google Scholar
• Mease PJ, Genovese MC, Greenwald MW, et al. Efficacy of brodalumab, an anti-IL-17R antibody, in subjects with psoriatic arthritis. Ann Rheum Dis 2013;72(Suppl 3):A85
   Google Scholar
• Genovese MC, Mease PJ, Greenwald MW, et al. Clinical response to brodalumab, an anti-interleukin-17 receptor antibody, in subjects with psoriatic arthritis. Arthritis Rheum 2013;65(Suppl 10):S347
   Google Scholar
• Johnson-Huang LM, Lowes MA, Krueger JG. Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Models Mech 2012;5(4):423-33
   PubMed Web of Science ®Google Scholar
• Sofen H, Smith S, Matheson R, et al. Results of a single ascending dose study to assess the safety and tolerability of CNTO 1959 following intravenous or subcutaneous administration in healthy subjects and in subjects with moderate to severe psosiasis. FC-21. Psoriasis: from Gene to Clinic 6th International Congress, 1-3 December 2011. Br J Dermatol 2011;165:e1-e46
   Google Scholar
• Grossman RM, Krueger J, Yourish D, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989;86(16):6367-71
   PubMed Web of Science ®Google Scholar
• van Kuijk AW, Tak PP. Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy. Curr Rheumatol Rep 2011;13(4):353-9
   PubMed Web of Science ®Google Scholar
• Atzeni F, Ventura D, Batticciotto A, et al. Interleukin 6 blockade: Tocilizumab in psoriatic arthritis. J Rheumatol Suppl 2012;89:97-9
   PubMedGoogle Scholar
• Emery P, Keystone E, Tony HP, et al. Il-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67(11):1516-23
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (option study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371(9617):987-97
   PubMed Web of Science ®Google Scholar
• Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58(10):2968-80
   PubMed Web of Science ®Google Scholar
• Sieper J, Porter-Brown B, Thompson L, et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 2014;73(1):95-100
   PubMed Web of Science ®Google Scholar
• Ogata A, Umegaki N, Katayama I, et al. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine 2012;79(1):85-7
   PubMed Web of Science ®Google Scholar
• Hughes M, Chinoy H. Successful use of tocilizumab in a patient with psoriatic arthritis. Rheumatology 2013;52(9):1728-9
   PubMed Web of Science ®Google Scholar
• Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against il-6ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised saril-ra-mobility part a trial. Ann Rheum Dis 2013; Epub ahead of print
   Google Scholar
• Sieper J, Inman RD, Badalamenti S, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a phase 2, randomized, double-blind, placebo-controlled, international study (ALIGN). Ann Rheum Dis 2012;71(Suppl 3):111
   Google Scholar
• Mease P, Strand V, Shalamberidze L, et al. A phase ii, double-blind, randomised, placebo-controlled study of bms945429 (ald518; in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis 2012;71(7):1183-9
   PubMed Web of Science ®Google Scholar
• Hsu B, Sheng S, Smolen JS, Weinblatt ME. Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2012;71(Suppl 3):188
   Web of Science ®Google Scholar
• Ritchlin C, Haas-Smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998;25(8):1544-52
   PubMed Web of Science ®Google Scholar
• Fiocco U, Sfriso P, Oliviero F, et al. Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-alpha blockade in the knee joint. Arthritis Res Ther 2010;12(4):R148
   PubMed Web of Science ®Google Scholar
• Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology 2007;46(7):1140-7
   PubMed Web of Science ®Google Scholar
• Jung N, Hellmann M, Hoheisel R, et al. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (mtx). Clin Rheumatol 2010;29(10):1169-73
   PubMed Web of Science ®Google Scholar
• Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125319s000_Lbl.pdf
   Google Scholar
• Alten R, Gomez-Reino J, Durez P, et al. Efficacy and safety of the human anti-il-1beta monoclonal antibody canakinumab in rheumatoid arthritis: Results of a 12-week, phase ii, dose-finding study. BMC Musculoskeletal Disord 2011;12:153
   PubMed Web of Science ®Google Scholar
• Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1beta monoclonal antibody. Clin Pharmacokinet 2012;51(6):e1-18
   PubMedGoogle Scholar
• Chimenti MS, Ballanti E, Perricone C, et al. Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev 2013;12(5):599-606
   PubMed Web of Science ®Google Scholar
• Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase ii trial. Arthritis Rheum 2011;63(4):939-48
   PubMed Web of Science ®Google Scholar
• Canete JD, Santiago B, Cantaert T, et al. Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis 2007;66(6):720-6
   PubMed Web of Science ®Google Scholar
• Veale D, Yanni G, Rogers S, et al. Reduced synovial membrane macrophage numbers, elam-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum 1993;36(7):893-900
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase iii trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54(9):2793-806
   PubMed Web of Science ®Google Scholar
• Cohen JD. Successful treatment of psoriatic arthritis with rituximab. Ann Rheum Dis 2008;67(11):1647-8
   PubMed Web of Science ®Google Scholar
• Jimenez-Boj E, Stamm TA, Sadlonova M, et al. Rituximab in psoriatic arthritis: an exploratory evaluation. Ann Rheum Dis 2012;71(11):1868-71
   PubMed Web of Science ®Google Scholar
• Wendling D, Dougados M, Berenbaum F, et al. Rituximab treatment for spondyloarthritis. A nationwide series: data from the air registry of the french society of rheumatology. J Rheumatol 2012;39(12):2327-31
   PubMed Web of Science ®Google Scholar
• Mease PJ. Is there a role for rituximab in the treatment of spondyloarthritis and psoriatic arthritis? J Rheumatol 2012;39(12):2235-7
   PubMed Web of Science ®Google Scholar
• Rigby W, Tony HP, Oelke K, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase iii trial. Arthritis Rheum 2012;64(2):350-9
   PubMed Web of Science ®Google Scholar
• Tak PP, Mease PJ, Genovese MC, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase iii trial. Arthritis Rheum 2012;64(2):360-70
   PubMed Web of Science ®Google Scholar
• Stohl W, Gomez-Reino J, Olech E, et al. Safety and efficacy of ocrelizumab in combination with methotrexate in mtx-naive subjects with rheumatoid arthritis: the phase iii film trial. Ann Rheum Dis 2012;71(8):1289-96
   PubMed Web of Science ®Google Scholar
• Jacques P, Van den Bosch F. Emerging therapies for rheumatoid arthritis. Expert Opin Emerg Drugs 2013;18(2):231-44
   PubMed Web of Science ®Google Scholar
• Taylor PC, Quattrocchi E, Mallett S, et al. Ofatumumab, a fully human anti-cd20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 2011;70(12):2119-25
   PubMed Web of Science ®Google Scholar
• Kurrasch R, Brown JC, Chu M, et al. Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase i/ii study of safety, tolerability, pharmacokinetics, and pharmacodynamics. J Rheumatol 2013;40(7):1089-96
   PubMed Web of Science ®Google Scholar
• Melchers F. Actions of baff in b cell maturation and its effects on the development of autoimmune disease. Ann Rheum Dis 2003;62(Suppl 2):ii25-7
   PubMedGoogle Scholar
• Stohl W, Merrill JT, McKay JD, et al. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase ii, randomized, double-blind, placebo-controlled, dose-ranging study. J Rheumatol 2013;40(5):579-89
   PubMed Web of Science ®Google Scholar
• Pongratz G, Straub RH, Scholmerich J, et al. Serum baff strongly correlates with psa activity in male patients only--is there a role for sex hormones? Clin Exp Rheumatol 2010;28(6):813-19
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377(9767):721-31
   PubMed Web of Science ®Google Scholar
• Genovese MC, Bojin S, Biagini IM, et al. Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase ii, randomized, placebo-controlled trial. Arthritis Rheum 2013;65(4):880-9
   PubMed Web of Science ®Google Scholar
• Genovese MC, Fleischmann RM, Greenwald M, et al. Tabalumab, an anti-baff monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to tnf inhibitors. Ann Rheum Dis 2013;72(9):1461-8
   PubMed Web of Science ®Google Scholar
• Genovese MC, Lee E, Satterwhite J, et al. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2013;72(9):1453-60
   PubMed Web of Science ®Google Scholar
• Genovese MC, Silverman GJ, Emery P, et al. Efficacy and safety of subcutaneous administration of tabalumab, an anti-B cell activating factor monoclonal antibody, in rheumatoid arthritis: results from a phase 3 multicenter, randomized, double-blind study. Arthritis Rheum 2013;65(Suppl 10):S733-4
   Google Scholar
• Koenders MI, Marijnissen RJ, Devesa I, et al. Tumor necrosis factor-interleukin-17 interplay induces s100a8, interleukin-1beta, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis. Arthritis Rheum 2011;63(8):2329-39
   PubMed Web of Science ®Google Scholar
• Buckland J. Experimental arthritis: therapeutic promise of dual blockade of il-17 and tnf in inflammatory arthritis. Nat Rev Rheumatol 2011;7(6):311
   PubMedGoogle Scholar
• Murumkar PR, Giridhar R, Yadav MR. Novel methods and strategies in the discovery of TACE inhibitors. Expert Opin Drug Discov 2013;8(2):157-81
   PubMed Web of Science ®Google Scholar
• Serwin AB, Sokolowska M, Chodynicka B. Tumour necrosis factor alpha (tnf-alpha)-converting enzyme (TACE) and soluble tnf-alpha receptor type 1 in psoriasis patients treated with narrowband ultraviolet b. Photodermatol Photoimmunol Photomed 2007;23(4):130-4
   PubMed Web of Science ®Google Scholar
• Ochaion A, Bar-Yehuda S, Cohn S, et al. Methotrexate enhances the anti-inflammatory effect of cf101 via up-regulation of the a3 adenosine receptor expression. Arthritis Res Ther 2006;8(6):R169
   PubMedGoogle Scholar
• Koscso B, Csoka B, Pacher P, Hasko G. Investigational a(3) adenosine receptor targeting agents. Expert Opin Investig Drugs 2011;20(6):757-68
   PubMed Web of Science ®Google Scholar
• Silverman MH, Strand V, Markovits D, et al. Clinical evidence for utilization of the a3 adenosine receptor as a target to treat rheumatoid arthritis: Data from a phase ii clinical trial. J Rheumatol 2008;35(1):41-8
   PubMed Web of Science ®Google Scholar
• David M, Akerman L, Ziv M, et al. Treatment of plaque-type psoriasis with oral cf101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol 2012;26(3):361-7
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009. Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf [Accessed 9 February 2014]
   Google Scholar
• Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of ct-p13 and innovator infliximab in patients with ankylosing spondylitis: the planetas study. Ann Rheum Dis 2013;72(10):1605-12
   PubMed Web of Science ®Google Scholar
• Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of ct-p13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the planetra study. Ann Rheum Dis 2013;72(10):1613-20
   PubMed Web of Science ®Google Scholar
• Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis 2013;72(10):1589-93
   PubMed Web of Science ®Google Scholar